Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Saizeng Medical Licenses TSHR Antibody to Yarrow for $1.4B in Graves’ Disease Deal

Fineline Cube Dec 16, 2025
Company Deals

uBriGene Partners with Circurna on circRNA Manufacturing for Global Trials

Fineline Cube Dec 16, 2025
Company Deals

Dren Bio, Sanofi Forge $1.8B B‑Cell Therapy Deal with US Co‑Promote Option

Fineline Cube Dec 16, 2025
Company Deals

Adaptive Licenses TCR Data to Pfizer in $890M Deal for Rheumatoid Arthritis

Fineline Cube Dec 16, 2025
Company Deals

Sobi Acquires Arthrosi for $1.5 Billion to Add Gout Drug to Portfolio

Fineline Cube Dec 15, 2025
Policy / Regulatory

FDA Removes Key RWE Limitation, Allowing Drug and Device Submissions Without Individual Patient Data

Fineline Cube Dec 16, 2025
Company Drug

Orelabrutinib First BTK Inhibitor to Hit Phase 3 in Lupus as InnoCare NMPA Filing Cleared

Fineline Cube Dec 16, 2025
Company Drug

ENHERTU Wins FDA Approval as First-Line HER2 Breast Cancer Therapy

Fineline Cube Dec 16, 2025
Company Drug

NMPA Accepts Roche’s Crovalimab Filing for PNH Treatment with Priority Review

Fineline Cube Aug 10, 2022

The National Medical Products Administration (NMPA) has officially accepted for review the market filing submitted...

Company Drug

Kintor Pharma Completes GT20029 Phase I Study for Hair Loss and Acne

Fineline Cube Aug 10, 2022

China-based Kintor Pharmaceutical Ltd (HKG: 9939) announced the completion of dosing all 92 subjects in...

Company Policy / Regulatory

NHSA Cracks Down on Price Gouging in Basic Medical Insurance Scheme

Fineline Cube Aug 10, 2022

The National Healthcare Security Administration (NHSA) has announced the results of a special investigation, revealing...

Company

FibroGen’s Roxadustat Sales in China Rise Despite Price Cut

Fineline Cube Aug 10, 2022

US firm FibroGen Inc. (NASDAQ: FGEN), which operates subsidiaries in Beijing and Shanghai, released its...

Company Drug

Inmagene and HutchMed Dose First Subject in IMG-004 Phase I Study

Fineline Cube Aug 10, 2022

China-based Inmagene Biopharmaceuticals and Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) announced that the...

Company

Zai Lab’s Q2 2022 Financials Show Revenue Growth and R&D Cost Cut

Fineline Cube Aug 10, 2022

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q2 2022 financial report,...

Company Drug

BeiGene’s Tislelizumab Meets Primary Endpoint in Global HCC Study

Fineline Cube Aug 10, 2022

BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced that the global Phase III RATIONALE 301...

Company Drug

Innovent Biologics’ IBI-112 Achieves Primary Endpoints in Psoriasis Phase II Trial

Fineline Cube Aug 10, 2022

China-based Innovent Biologics Inc. (HKG: 1801) announced that its interleukin-23 subunit p19 (IL-23p19) monoclonal antibody...

Company Drug

Sciwind’s XW003 Shows Positive Weight Loss Results in Phase Ic/IIa Study

Fineline Cube Aug 9, 2022

Hangzhou-based Sciwind announced positive interim topline results from a 26-week Phase Ic/IIa clinical study of...

Company Deals

Hansoh Pharma Licenses TiumBio’s TU2670 for Endometriosis Treatment in Greater China

Fineline Cube Aug 9, 2022

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced a licensing agreement with South Korea’s...

Company Drug

Gan & Lee Pharmaceuticals’ GZR4 Wins FDA Approval for Diabetes Treatment

Fineline Cube Aug 9, 2022

China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that it has received clinical trial approval...

Medical Device

GeneoDx Biotech’s Cervical Cancer Screening Kit Wins NMPA Approval

Fineline Cube Aug 9, 2022

Shanghai GeneoDx Biotech Co., Ltd, a medical diagnosis unit of Sinopharm, has announced that it...

Medical Device

MicroPort CardioFlow Medtech’s VitaFlow Liberty and Angelguide Approved in Colombia

Fineline Cube Aug 9, 2022

China-based MicroPort Scientific Corp’s (HKG: 0853) spin-off MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) announced...

Company Drug

HeNan Genuine Biotech Sets Azvudine Price at RMB300 per Bottle for COVID-19 Therapy

Fineline Cube Aug 9, 2022

China-based HeNan Genuine Biotech Co., Ltd has set the price of its COVID-19 therapy azvudine...

Company Deals

Sinotherapeutics Inc. to Raise RMB600m via STAR Board IPO for Generic Drug Expansion

Fineline Cube Aug 9, 2022

Sinotherapeutics Inc., a Shanghai-based generic drug developer, is set to make an initial public offering...

Policy / Regulatory R&D

CDE Issues Q&As on COVID-19 Antiviral Drug Evaluation Criteria

Fineline Cube Aug 9, 2022

The Center for Drug Evaluation (CDE) has published a list of Q&As regarding the non-clinical...

Company Medical Device

NMPA Approves BioFire Diagnostics’ Encephalitis/Meningitis Detection Kit

Fineline Cube Aug 9, 2022

The National Medical Products Administration (NMPA) website indicates that BioFire Diagnostics LLC’s encephalitis/meningitis multiple pathogen...

Company Deals R&D

BioDuro-Sundia and X-Chem Form Long-Term Partnership for Drug Discovery

Fineline Cube Aug 8, 2022

Two China-based companies, the Contract Research, Development, and Manufacturing Organization (CRDMO) BioDuro-Sundia and X-Chem, have...

Company Drug

Dizal Pharma’s Sunvozertinib Shows Promise in NSCLC with EGFR Exon 20 Insertion

Fineline Cube Aug 8, 2022

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has unveiled the latest positive data for its...

Company Deals Digital

Hywin Holdings to Acquire Life Infinity for Health Management Expansion

Fineline Cube Aug 8, 2022

China-based wealth management firm Hywin Holdings is set to move into the health management business...

Posts pagination

1 … 571 572 573 … 598

Recent updates

  • Orelabrutinib First BTK Inhibitor to Hit Phase 3 in Lupus as InnoCare NMPA Filing Cleared
  • Saizeng Medical Licenses TSHR Antibody to Yarrow for $1.4B in Graves’ Disease Deal
  • Zhicheng’s TAVR Robotic System Enters NMPA Innovation Pathway
  • ENHERTU Wins FDA Approval as First-Line HER2 Breast Cancer Therapy
  • FDA Removes Key RWE Limitation, Allowing Drug and Device Submissions Without Individual Patient Data
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Orelabrutinib First BTK Inhibitor to Hit Phase 3 in Lupus as InnoCare NMPA Filing Cleared

Company Deals

Saizeng Medical Licenses TSHR Antibody to Yarrow for $1.4B in Graves’ Disease Deal

Company Medical Device

Zhicheng’s TAVR Robotic System Enters NMPA Innovation Pathway

Company Drug

ENHERTU Wins FDA Approval as First-Line HER2 Breast Cancer Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.